ArticleHealth science reports2026
Advancing the Diagnosis of Non-Hodgkin Lymphoma Through Next-Generation Sequencing in Developing Countries: An Evaluation of Progress-A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Non-Hodgkin lymphoma (NHL) is the most prevalent hematological malignancy worldwide and accounts for approximately 3% of all cancer cases and fatalities. Next-generation sequencing (NGS) has advanced molecular diagnosis and targeted treatment in developed countries. However, developing countries face barriers like limited infrastructure, funding, and expertise, hindering wide NGS adoption. This narrative review evaluates the progress, challenges, and feasibility of using NGS for NHL diagnosis in developing countries. Methods: A comprehensive narrative literature review was conducted. We searched the PubMed, Scopus, and Google Scholar databases for relevant English-language articles published between January 2008 and December 2025. The focus was on synthesizing evidence from studies applying NGS for NHL diagnosis, with particular emphasis on data from developing countries and comparisons with advancements in developed regions. Results: NGS has improved NHL subclassification accuracy and identified clinically relevant mutations, enabling personalized therapies. Studies from China, India, and South Africa demonstrate successful implementation of panel-based NGS strategies. Despite this, challenges persist, including high costs, lack of standardized protocols, infrastructural deficits, and workforce shortages, limiting broader utilization in resource-limited settings. Collaborative efforts and investments have begun to address these issues in some developing countries. Conclusion: NGS promises significant benefits in NHL diagnosis and management in developing countries. Overcoming financial, technical, and training barriers through targeted policies, funding, and international cooperation is crucial to harnessing its full potential. With ongoing advancements, NGS is poised to become a crucial tool for diagnosis and guiding therapy worldwide, including in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.